Royce & Associates LP Makes New Investment in Definium Therapeutics, Inc. $DFTX

Royce & Associates LP acquired a new stake in shares of Definium Therapeutics, Inc. (NASDAQ:DFTX) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 81,024 shares of the company’s stock, valued at approximately $955,000.

Several other hedge funds have also recently modified their holdings of the stock. Stoneridge Investment Partners LLC grew its position in shares of Definium Therapeutics by 7.5% during the third quarter. Stoneridge Investment Partners LLC now owns 11,563 shares of the company’s stock valued at $136,000 after purchasing an additional 804 shares in the last quarter. Cerity Partners LLC boosted its position in shares of Definium Therapeutics by 2.4% during the 2nd quarter. Cerity Partners LLC now owns 49,650 shares of the company’s stock valued at $322,000 after acquiring an additional 1,165 shares during the last quarter. Teacher Retirement System of Texas grew its holdings in shares of Definium Therapeutics by 9.4% in the second quarter. Teacher Retirement System of Texas now owns 16,260 shares of the company’s stock valued at $106,000 after purchasing an additional 1,400 shares in the last quarter. Creative Planning increased its position in Definium Therapeutics by 2.6% in the second quarter. Creative Planning now owns 66,097 shares of the company’s stock worth $429,000 after purchasing an additional 1,655 shares during the last quarter. Finally, CWM LLC raised its stake in Definium Therapeutics by 67.4% during the second quarter. CWM LLC now owns 4,459 shares of the company’s stock valued at $29,000 after purchasing an additional 1,796 shares in the last quarter. Hedge funds and other institutional investors own 27.91% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently commented on DFTX. Royal Bank Of Canada increased their price target on shares of Definium Therapeutics from $20.00 to $36.00 and gave the company an “outperform” rating in a report on Friday, January 23rd. Robert W. Baird set a $37.00 price objective on Definium Therapeutics in a research report on Thursday, January 29th. Chardan Capital raised Definium Therapeutics to a “strong-buy” rating in a research note on Wednesday, November 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Definium Therapeutics in a report on Thursday, January 22nd. Finally, Wolfe Research initiated coverage on Definium Therapeutics in a research report on Monday, February 23rd. They set an “outperform” rating and a $25.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Definium Therapeutics currently has an average rating of “Buy” and a consensus target price of $35.70.

Insider Activity at Definium Therapeutics

In other news, insider Mark Sullivan sold 11,276 shares of the firm’s stock in a transaction dated Friday, December 26th. The stock was sold at an average price of $13.15, for a total value of $148,279.40. Following the completion of the transaction, the insider directly owned 282,576 shares in the company, valued at $3,715,874.40. This trade represents a 3.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Daniel Karlin sold 5,600 shares of the firm’s stock in a transaction on Friday, December 26th. The stock was sold at an average price of $13.15, for a total transaction of $73,640.00. Following the transaction, the insider directly owned 425,025 shares of the company’s stock, valued at approximately $5,589,078.75. This trade represents a 1.30% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 42,667 shares of company stock valued at $561,071 in the last ninety days. Company insiders own 2.26% of the company’s stock.

Key Stories Impacting Definium Therapeutics

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: HC Wainwright kept a “Buy” rating and a $70 price target while materially raising long-range earnings forecasts (FY2028–FY2030: FY2028 to $0.72, FY2029 to $3.24, FY2030 to $5.32), supporting a bullish long-term thesis for DFTX. MarketBeat DFTX report
• Neutral Sentiment: Sector news: a Psychedelic roundup highlighted Helus Pharma’s Phase 2 HLP004 results — relevant for overall psychedelic/psychedelics-adjacent sentiment but not directly related to Definium’s programs. This can move group sentiment without directly changing DFTX fundamentals. Psychedelic: Helus Pharma reports HLP004 Phase 2 signal detection study results
• Neutral Sentiment: Short-interest data reported a “large increase” but shows 0 shares and NaN change — likely a data/reporting anomaly. There’s no clear evidence of rising short pressure based on the provided figures, so this item shouldn’t be driving the move unless updated data appears.
• Negative Sentiment: HC Wainwright cut near-term estimates: quarterly EPS for Q1–Q4 2026 were lowered to ($0.46) from ($0.38) and FY2026/FY2027 forecasts were reduced (FY2026 now ($1.83) vs prior ($1.52); FY2027 now ($1.52) vs prior ($1.23)). Those nearer-term downgrades increase downside risk for the next 12–18 months and can weigh on sentiment despite the long-term upside case. MarketBeat DFTX report

Definium Therapeutics Trading Up 0.6%

NASDAQ DFTX opened at $17.66 on Friday. Definium Therapeutics, Inc. has a 52 week low of $4.70 and a 52 week high of $18.70. The company has a 50 day moving average price of $16.08 and a 200 day moving average price of $13.07. The company has a quick ratio of 6.29, a current ratio of 6.29 and a debt-to-equity ratio of 0.12. The firm has a market cap of $1.74 billion, a PE ratio of -8.29 and a beta of 2.56.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.